Last reviewed · How we verify
NCT04567082: PROMEO
Proteome- and Methylation Profiles in Oropharyngeal Cancer
trial testing Examination of saliva in Oropharynx Cancer in 45 participants. Completed in 31 January 2024.
31 January 2024
Quick facts
| Lead sponsor | Aalborg University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 45 |
| Start date | 25 September 2020 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Examination of saliva
Conditions studied
- Oropharynx Cancer — all drugs for Oropharynx Cancer →
Sponsor
Aalborg University Hospital
Who can join
18 and older, any sex, with Oropharynx Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical study aims to evaluate proteome- and methylation profiles in saliva in patients with oropharyngeal cancers
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04567082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oropharynx Cancer
Currently open trials in the same condition.
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
- NCT07033091 — Prevalence of Human Papillomavirus (HPV) in a Healthy Population: A Feasibility Study of Oropharyngeal Cancer Screening · NA · recruiting
- NCT06309225 — Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly · NA · recruiting
- NCT06563362 — Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
Other Aalborg University Hospital trials
Trials by the same sponsor.
- NCT06960005 — ThyMoves: Screening and Exercise to Improve Muscle, Enhance Quality of Life, and Reduce Fall Risk in Thyroid Disease · NA · enrolling by invitation
- NCT06745544 — Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes · NA · recruiting
- NCT07185958 — Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy · not yet recruiting
- NCT07165574 — Prevalence of Anticholinergics in Geriatric Patients With Acute Functional Deterioration · not yet recruiting
- NCT07173413 — Assessing the Quality of Telephone Follow-Up After Spine Surgery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04567082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aalborg University Hospital
- Last refreshed: 2 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04567082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing